Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that its abstract detailing clinical results ongoing Phase 1/2 trial ...

In recent years, the increase in knowledge about the functioning of the immune system has revealed not only its importance in ...

Despite advances in the field of organ transplantation, long-term organ rejection that can become apparent a decade or more ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of ...

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to ...

An investigational antibody could reduce the toxicity associated with immune suppression in islet cell transplantation for type 1 diabetes (T1D), according to new preliminary data. Six people with T1D ...

Islet cell therapy, which involves infusing insulin-producing cells, has helped some people with type 1 diabetes achieve insulin independence. After receiving the islet cells, long-term ...

As the global population ages, the number of kidney transplant recipients aged ≥ 65 years is rising, challenging clinicians to refine immunosuppressive strategies that balance rejection prevention ...

A new review highlights sepsis-induced immunosuppression as a key driver of mortality, summarizing current research and outlining priorities for future study. Despite advances, research progress on ...

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate below 10%. University of Cincinnati Cancer Center researchers examined the unique tumor ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the formation of blood vessels. However, the circulatory system is not the only ...

Three-fourths of kidney transplant patients in a small trial avoided long-term immunosuppression using a donor-derived cellular therapy. No deaths, graft loss, or complications occurred in the ...